Bridging the Gap: How Real-World Intelligence Is Overcoming Phase III Trial Delays
Bringing a new CNS drug to market is notoriously challenging. Billions of dollars and years of R&D often meet a final roadblock in Phase III, when execution misalignment stalls progress.
The Challenge
The journey of bringing a new central nervous system (CNS) drug to market is notoriously challenging. Across biopharma, billions of dollars and years of meticulous research are routinely poured into clinical development, only to hit a massive roadblock during Phase III.
The Real-World Disconnect
Why Phase III CNS Trials Stall
The root cause of most Phase III delays rarely stems from a lack of scientific rigor. Instead, it is usually a misalignment between clinical protocol design and real-world clinical practice.
When protocols are built in a clinical vacuum, eligibility criteria look flawless on paper but fail to reflect how CNS disease is managed in the community.
- Overly Restrictive Eligibility: Excluding patients with common comorbidities can shrink the available pool to a fraction of a percent.
- Flawed Site Selection: Relying on historical site performance without verifying current patient flow or local referral networks.
- High Patient Burden: Excess clinic visits and invasive procedures drive dropout rates sharply higher.
The Solution
Real-World Expert Intelligence for Aligned Execution
Forward-thinking biopharma companies are shifting from purely protocol-driven designs to real-world aligned execution, using AI together with specialized human networks to validate and optimize trial plans.
Strategic Intelligence
Activating Expert Networks
Local neurologists and clinical investigators are engaged before and during site selection to validate eligibility, surface recruitment barriers, and identify current high-performing geographies.
- Validating whether theoretical eligibility criteria match the patient profiles actually seen in clinics.
- Outlining recruitment barriers that algorithms may miss.
- Pinpointing high-performing trial geographies based on active patient densities.
AI + Human Insight
Translating Feedback into Execution
Structured qualitative insights are paired with AI-driven benchmarking to turn fragmented feedback into execution-ready strategies that improve site performance and reduce dropout risk.
- Turning expert input into dynamic trial optimization plans.
- Mitigating site and patient risks before they threaten enrollment.
- Aligning trial execution with how care is delivered in the real world.
Business Impact
Real-World Validation That Accelerates CNS Trials
Addressing protocol-to-practice gaps delivers more than operational improvements: it unlocks faster enrollment, stronger retention, and a higher probability of trial success.
Re-aligning criteria unlocks immediate access to viable patient pathways.
Eliminating enrollment bottlenecks shaves months off the development runway.
Better retention and cleaner data keep the study on a definitive path to approval.
FAQ
.webp)